SUVENPHAR

Suven Pharmaceuticals Share Price

₹1,032.55 -21.15 (-2.01%)

22 Jan, 2025 12:35

SIP TrendupStart SIP in SUVENPHAR

Start SIP

Performance

  • Low
  • ₹1,030
  • High
  • ₹1,065
  • 52 Week Low
  • ₹585
  • 52 Week High
  • ₹1,360
  • Open Price₹1,045
  • Previous Close₹1,054
  • Volume246,892

Investment Returns

  • Over 1 Month -12.88%
  • Over 3 Month -19.13%
  • Over 6 Month + 25.83%
  • Over 1 Year + 45.78%
SIP Lightning

Smart Investing Starts Here Start SIP with Suven Pharmaceuticals for Steady Growth!

Invest Now

Suven Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 108.1
  • PEG Ratio
  • -2.5
  • Market Cap Cr
  • 26,285
  • P/B Ratio
  • 13.3
  • Average True Range
  • 41.98
  • EPS
  • 9.55
  • Dividend Yield
  • 0
  • MACD Signal
  • -43.54
  • RSI
  • 29.73
  • MFI
  • 48.44

Suven Pharmaceuticals Financials

Suven Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,032.55
-21.15 (-2.01%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹1,104.75
  • 50 Day
  • ₹1,159.17
  • 100 Day
  • ₹1,140.23
  • 200 Day
  • ₹1,029.26

Resistance and Support

1056.33 Pivot Speed
  • R3 1,156.12
  • R2 1,123.73
  • R1 1,088.72
  • S1 1,021.32
  • S2 988.93
  • S3 953.92

What's your outlook on Suven Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Suven Pharmaceuticals Ltd. is a leading pharmaceutical company specializing in contract development and manufacturing services (CDMO). It focuses on producing intermediates and active pharmaceutical ingredients (APIs), serving global pharmaceutical companies with innovative and high-quality solutions.

Suven Pharmaceuticals has an operating revenue of Rs. 961.16 Cr. on a trailing 12-month basis. An annual revenue de-growth of -20% needs improvement, Pre-tax margin of 39% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 8% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 38 which is a POOR score indicating inconsistency in earnings, a RS Rating of 73 which is FAIR indicating the recent price performance, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Suven Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results
2024-08-09 Quarterly Results
2024-05-30 Audited Results (Revised) per share(100%)Interim Dividend
2024-02-05 Quarterly Results
Date Purpose Remarks
2022-09-12 INTERIM Rs.1.00 per share(100%)Interim Dividend
2022-09-12 SPECIAL Rs.5.00 per share(500%)Special Dividend
2022-05-17 INTERIM Re.1.00 per shaer (100%) Second Interim Dividend
2022-05-17 SPECIAL Rs.1.00 per share(100%)Special Dividend
2022-02-16 INTERIM Rs.1.00 per share(100%)Interim Dividend
View More

Suven Pharmaceuticals F&O

Suven Pharmaceuticals Shareholding Pattern

50.1%
13.15%
3.2%
10.84%
0%
9.81%
12.9%

About Suven Pharmaceuticals

  • NSE Symbol
  • SUVENPHAR
  • BSE Symbol
  • 543064
  • Managing Director
  • Dr. V Prasada Raju
  • ISIN
  • INE03QK01018

Similar Stocks to Suven Pharmaceuticals

Suven Pharmaceuticals FAQs

Suven Pharmaceuticals share price is ₹1,032 As on 22 January, 2025 | 12:21

The Market Cap of Suven Pharmaceuticals is ₹26285.1 Cr As on 22 January, 2025 | 12:21

The P/E ratio of Suven Pharmaceuticals is 108.1 As on 22 January, 2025 | 12:21

The PB ratio of Suven Pharmaceuticals is 13.3 As on 22 January, 2025 | 12:21

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23